Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib.
Sci Rep
January 2025
Department of Hepatobiliary and Pancreatic Surgery, Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Pembrolizumab plus Lenvatinib is regarded as a significant treatment option for advanced unresectable hepatocellular carcinoma (HCC). This study aims to meticulously monitor and identify adverse events (AEs) related to this combined therapy, enhance patient safety, and offer evidence-based recommendations for the appropriate use of these drugs. We gathered adverse drug reactions (ADRs)-related data from the FAERS database for HCC patients who received Pembrolizumab, both alone and in combination with Lenvatinib from the first quarter of 2014 to the fourth quarter of 2023.
View Article and Find Full Text PDFA chlorin e6 derivative-mediated photodynamic therapy versus doxycycline for moderate-to-severe rosacea: A prospective, randomized, controlled study.
Photodiagnosis Photodyn Ther
January 2025
Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200443, China. Electronic address:
Background: Photodynamic therapy (PDT) is beneficial for managing rosacea, and chlorin e6 derivative-mediated photodynamic therapy (STBF-PDT) has demonstrated efficacy in reducing acne lesions with mild adverse reactions.
Objectives: This study aimed to assess the effectiveness and safety of STBF-PDT for the treatment of moderate-to-severe rosacea.
Methods: In this prospective, randomised, evaluator-blind controlled study, patients with moderate-to-severe rosacea were assigned to receive up to six STBF-PDT sessions or 100 mg of doxycycline daily for eight weeks, followed by a 24-week follow-up.
Au nanoparticles anchored carbonized ZIF-8 for enabling real-time and noninvasive glucose monitoring in sweat.
Biosens Bioelectron
January 2025
Jiangsu Key Laboratory of Advanced Catalytic Materials and Technology, School of Petrochemical Engineering, Changzhou University, 213164, Changzhou, China. Electronic address:
Wearable sensors can easily enable real-time and noninvasive glucose (Glu) monitoring, providing vital information for effectively preventing various complications caused by high glucose level. Here, a wearable sensor based on nanozyme-catalyzed cascade reactions is designed for Glu monitoring in sweat. Au nanoparticles (AuNPs) are anchored to the carbonated zeolitic imidazolate framework-8 (ZIF-8-C), endowing the sensor with Glu oxidase (GOx)-like and peroxidase (POD)-like activity.
View Article and Find Full Text PDFAcute exposure to nitrogen mustard induces rapid nuclear component regulation and delayed stress to exogenous stimuli.
Int Immunopharmacol
January 2025
Clinical and Public Health Research Center, Women and Children's Hospital of Chongqing Medical University, Chongqing, China; Chongqing Health Center for Women and Children, Chongqing, China; Chongqing Research Center for Prevention & Control of Matermal and Child Disease and Public Health, Chongqing, China. Electronic address:
Nitrogen mustard (NM) is a vesicant agent with potent toxic effects on various tissues. Numerous theories have been proposed to explain its toxic mechanisms, yet research on the interconnections among these theories is lacking. This study focuses on analyzing the characteristics of genes involved in NM-induced bronchial injury within the Comparative Toxicogenomics Database (CTD).
View Article and Find Full Text PDFTrastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
J Clin Oncol
January 2025
Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Purpose: Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.
Methods: In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!